| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_408a673e5f3674e77d63dfe2a7856215 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1841
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 |
| filingDate |
2008-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fa7719760ef04a471a684053360c805
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fad061c649eefaf9c6f48a492e2c0aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e4769d1e16bdd74ee146beeb1dfec14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b5511e3890fdd685192023e4f6a70e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b5036b178453118f9713cfa68457b62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cacac742723cce6bfce7ae32d198a26d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c690d9924881241edff76bbca19ee93 |
| publicationDate |
2011-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011152189-A1 |
| titleOfInvention |
Methods for the inhibition of scarring |
| abstract |
The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be formed, is provided with between approximately 350 ng and 1000 ng of TGF-β3; and in a second incidence of treatment, occurring after a wound is formed, and between 8 and 48 hours after the first incidence of treatment, the wound is provided with an amount of between approximately 350 ng and 1000 ng of TGF-β3 per centimetre of wound margin in which scarring is to be inhibited. The amount of TGF-β3 provided may be the same in each incidence of treatment. The amount of TGF-β3 provided per centimetre in each incidence of treatment may preferably be approximately 500 ng. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound. |
| priorityDate |
2007-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |